Century Therapeutics, Inc. (IPSC)
NASDAQ: IPSC · Real-Time Price · USD
2.345
+0.085 (3.76%)
Jul 17, 2026, 11:47 AM EDT - Market open
Century Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 51.05 | 61.85 | 58.44 | 47.32 | 84.27 | 56.45 |
Short-Term Investments | 83.76 | 55.26 | 130.85 | 125.41 | 231.23 | 166.43 |
Cash & Short-Term Investments | 134.8 | 117.11 | 189.29 | 172.74 | 315.5 | 222.88 |
Cash Growth | -18.36% | -38.13% | 9.58% | -45.25% | 41.56% | 194.22% |
Other Current Assets | 4.24 | 3.66 | 4.76 | 4.26 | 4.22 | 5.28 |
Total Current Assets | 139.04 | 120.77 | 194.05 | 176.99 | 319.72 | 228.15 |
Net Property, Plant & Equipment | 68.58 | 66.17 | 90.85 | 92.08 | 111.73 | 69.82 |
Other Intangible Assets | 34.2 | 34.2 | 34.2 | - | - | - |
Long-Term Investments | 82.17 | - | 30.82 | 89.1 | 51.85 | 135.91 |
Other Long-Term Assets | 2.57 | 2.57 | 3.3 | 2.52 | 3.24 | 3.49 |
Total Assets | 326.55 | 223.7 | 353.22 | 360.69 | 486.54 | 437.38 |
Accounts Payable | 3.15 | 4.77 | 3.08 | 2.74 | 5.45 | 7.6 |
Accrued Expenses | 8.48 | 11.68 | 17.46 | 10.15 | 9.84 | 6.04 |
Current Portion of Long-Term Debt | - | - | - | - | 6.5 | 1.04 |
Unearned Revenue | - | - | 109.16 | 4.37 | 7.15 | 0 |
Other Current Liabilities | 1.94 | 3.78 | 0.08 | 0.58 | 0.87 | 0.98 |
Total Current Liabilities | 13.57 | 20.23 | 129.78 | 17.85 | 29.82 | 15.66 |
Long-Term Debt | - | - | - | - | 3.74 | 8.9 |
Long-Term Leases | 43.94 | 40.24 | 48.96 | 46.66 | 38.7 | 14.56 |
Other Long-Term Liabilities | 4.3 | 4.3 | 13.11 | 111.44 | 111.55 | 2.02 |
Total Long-Term Liabilities | 48.24 | 44.54 | 62.07 | 158.1 | 153.99 | 25.48 |
Total Liabilities | 61.81 | 64.77 | 191.85 | 175.94 | 183.81 | 41.14 |
Common Stock | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 1,079 | 950.81 | 943.37 | 840.41 | 824.29 | 785.05 |
Accumulated Other Comprehensive Income | -0.59 | 0.03 | 0.32 | 0.11 | -2.46 | -0.65 |
Retained Earnings | -813.56 | -791.92 | -782.34 | -655.77 | -519.1 | -388.17 |
Shareholders' Equity | 264.74 | 158.94 | 161.36 | 184.75 | 302.74 | 396.24 |
Total Liabilities & Equity | 326.55 | 223.7 | 353.22 | 360.69 | 486.54 | 437.38 |
Total Debt | 43.94 | 40.24 | 48.96 | 46.66 | 48.94 | 24.5 |
Net Cash (Debt) | 90.86 | 76.87 | 140.33 | 126.08 | 266.56 | 198.38 |
Net Cash Growth | 18.20% | -45.22% | 11.30% | -52.70% | 34.37% | 264.41% |
Net Cash Per Share | 0.80 | 0.89 | 1.78 | 2.13 | 4.62 | 6.12 |
Book Value | 264.74 | 158.94 | 161.36 | 184.75 | 302.74 | 396.24 |
Book Value Per Share | 2.34 | 1.84 | 2.05 | 3.11 | 5.24 | 12.23 |
Tangible Book Value | 230.54 | 124.74 | 127.16 | 184.75 | 302.74 | 396.24 |
Tangible Book Value Per Share | 2.03 | 1.44 | 1.62 | 3.11 | 5.24 | 12.23 |